Every Tunio report - whether a broad screening or a specialized panel - is sequenced at our partner lab, backed by the institutional accreditations behind every result they produce.
ISO 15189 is the accreditation that separates a medical laboratory from a testing service. It requires documented competence in every stage of the testing process - from sample receipt to result delivery. Our partner lab holds this accreditation as an operating standard.
The College of American Pathologists accreditation is the most rigorous laboratory quality program in existence. CAP inspects our partner lab through unannounced on-site inspections - reviewing every process from reagent handling to result interpretation. It is the standard hospitals use to approve laboratories for clinical use.
Clinical Laboratory Improvement Amendments (CLIA) certification is the federal standard that authorizes a laboratory to perform clinical testing on human specimens in the United States. Our partner lab's results - sequenced at 30X coverage with 99.98% accuracy - meet the standard required for clinical use in US medical decision-making, as clinical-grade findings a physician can act on.
Every variant identified through our partner lab's sequencing is classified according to guidelines from the American College of Medical Genetics and Genomics and the Association for Molecular Pathology (ACMG/AMP) - the international standard for clinical variant interpretation. The same framework used by Mayo Clinic, Johns Hopkins, NHS genetics, and major academic medical centers worldwide.
Our partner lab has generated more than 1 million clinical reports to date.
Sample data only. The findings below are fictional examples used to illustrate the real report format. They are not derived from any real person's DNA and aren't a preview of any actual customer's results.
Tunio Exome and Tunio Genome both screen your DNA against hundreds of thousands of known clinical variants, not a handful of genes - and both report findings in the exact same format shown below. The only difference is scope.
~20,000 protein-coding genes - the ~2% of your genome where roughly 85% of known disease-linked variants sit.
Your entire genome: every protein-coding gene, plus the non-coding and regulatory regions Exome doesn't cover.
Beyond Exome and Genome, we offer deep, single-condition panels - cardiology, endocrinology, fertility, rare disease, and more - built on the same clinical-grade analysis. A few examples:
Don't see the condition you're looking for? Our full library spans 150+ specialized panels.
Request a specialized panelReports use the same clinical classification system geneticists use (ACMG/ClinVar) - here's what each one actually means.
A well-established, disease-causing change. The strongest level of evidence a variant can have.
Strong evidence points to a disease-causing effect, just short of definitive.
Not enough evidence yet to call it harmful or harmless - reported for completeness, not for action.
No evidence of harm - either the variant is common and harmless, or nothing reportable was found at all.
Tunio Exome - sample
| Gene | Variant | Classification | Zygosity | Condition |
|---|---|---|---|---|
| LDLR | c.681C>G (p.Asn227Lys) | Pathogenic | Heterozygous | Familial hypercholesterolemia |
| MUTYH | c.536A>G (p.Tyr179Cys) | Likely Pathogenic | Heterozygous | MUTYH-associated polyposis (carrier) |
| CYP2C19 | *2/*2 | Drug response | Homozygous | Reduced clopidogrel (Plavix) metabolism |
Every reportable variant is listed this way - gene, exact change, clinical classification, and the condition(s) it's linked to.
Tunio Exome - sample
10:93410 C>T
rs782575307 · NM_177987.3(TUBB8):c.922G>A (p.Gly308Ser)
Phenotype
Oocyte maturation defect 2
ACMG evidence (InterVar)
PM1 ↑PM1: located in a mutational hot spot or well-established functional domain - one contributing line of evidence, which is why ACMG's automated call (Uncertain Significance) is more conservative than ClinVar's own curated classification (Pathogenic) here. Both are shown, since they don't always agree.
Tunio Exome - sample
20,000+ genes are checked against every known clinically significant variant. Most - like the ones above - simply show nothing to report, which is exactly what you want to see.
Sample finding
| Gene | Variant | Classification | Zygosity | Condition |
|---|---|---|---|---|
| APOE | rs429358 (ε4 allele) | Likely Pathogenic / Risk factor | Heterozygous | Coronary artery disease risk, Alzheimer disease, Warfarin sensitivity |
320+ genes analyzed, covering the full range of inherited heart and vascular conditions - not just a handful of common markers.
Sample finding
No pathogenic or likely pathogenic variants detected across all 54 genes analyzed for this panel.
A clear result doesn't rule out risk from lifestyle or family history - it means we found nothing on the specific genetic causes this panel screens for.
Sample finding
| Gene | Variant | Classification | Zygosity | Condition |
|---|---|---|---|---|
| DUOX2 | c.3449A>G (p.Tyr1150Cys) | Uncertain Significance | Heterozygous | Thyroid dyshormonogenesis 6 |
Uncertain-significance findings are reported for completeness, but aren't acted on alone - they simply reflect that science hasn't reached a clear answer yet for this specific change.